

Skylark Clinic, Inc.

Doing Business As

Skylark

Financial Statements and Auditors' Report

For the Years Ended

December 31, 2024 and 2023

Table of Contents

Independent Auditors' Report	1-2
Financial Statements	
Statement of Financial Position	3-4
Statements of Activities	5
Statement of Cash Flows	6
Statements of Functional Expenses	7
Notes to the Financial Statements	8-15

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors
of Skylark Clinic, Inc.
d/b/a Skylark
Brunswick, Georgia

Opinion

We have audited the accompanying financial statements of Skylark Clinic, Inc. (a nonprofit organization), which comprise the statement of financial position as of December 31, 2024, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Skylark Clinic, Inc. as of December 31, 2024, and the changes in net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Skylark Clinic, Inc. and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Skylark Clinic, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance

and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Skylark Clinic, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Skylark Clinic, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We did not previously audit Skylark Clinic, Inc.'s 2024 financial statements, and we do not express an opinion on those audited financial statements in our report.



Harris & Company, PC

Jesup, Georgia

May 15, 2025

Skylark Clinic, Inc.
d/b/a Skylark
Statement of Financial Position
As of December 31, 2024
(with summarized comparative information for 2023)

	Without Donor Restrictions	With Donor Restrictions	Total	2023
Assets				
Current Assets				
Cash and cash equivalents	388,118	257,823	645,941	341,013
Inventory	110,780		110,780	88,967
Pledge Receivables, net	49,992	950,401	1,000,393	950,053
Prepaid Expenses	19,786		19,786	21,153
Investments		507,113	507,113	344,427
Total Current Assets	<u>568,676</u>	<u>1,715,337</u>	<u>2,284,013</u>	<u>1,745,613</u>
Fixed Assets				
Construction in progress	-	107,950	107,950	27,535
Land	125,000	-	125,000	125,000
Buildings	178,718	-	178,718	165,818
Furniture and Equipment	631,770	-	631,770	631,770
	<u>935,488</u>	<u>107,950</u>	<u>1,043,438</u>	<u>950,123</u>
Less: Accumulated Depreciation	(655,115)	-	(655,115)	(620,651)
 Intangible Right to use assets	<u>659,749</u>	<u>-</u>	<u>659,749</u>	<u>659,749</u>
Less: Accumulated Amortization	(152,250)	-	(152,250)	(101,500)
Fixed Assets, Net	<u>787,872</u>	<u>107,950</u>	<u>895,822</u>	<u>887,721</u>
Other Assets				
Donated property held for sale	22,692		22,692	705
Refundable deposits	5,140		5,140	5,140
Total Other Assets	<u>27,832</u>	<u>-</u>	<u>27,832</u>	<u>5,845</u>
Total Assets	<u>1,384,380</u>	<u>1,823,287</u>	<u>3,207,667</u>	<u>2,639,179</u>

The accompanying notes to the financial statements
are an integral part of this statement.

Skylark Clinic, Inc.
d/b/a Skylark
Statement of Financial Position
As of December 31, 2024
(with summarized comparative information for 2023)

	Without Donor Restrictions	With Donor Restrictions	Total	2023
Liabilities and Net Assets				
Current Liabilities				
Accounts Payable	50,308	-	50,308	18,165
Accrued Expenses	12,350	-	12,350	33,408
Lease payable due in one year	48,865	-	48,865	32,612
Total Current Liabilities	<u>111,523</u>	<u>-</u>	<u>111,523</u>	<u>84,185</u>
Long-term Liabilities				
Lease Payable due in more than one year	519,090	-	519,090	567,955
Total Long-term Liabilities	<u>519,090</u>	<u>-</u>	<u>519,090</u>	<u>567,955</u>
Total Liabilities	<u>630,613</u>	<u>-</u>	<u>630,613</u>	<u>652,140</u>
Without donor restrictions:				
Board-Designated	250,000	-	250,000	250,000
Undesignated	503,767	-	503,767	659,367
Total without donor restrictions	<u>753,767</u>	<u>-</u>	<u>753,767</u>	<u>909,367</u>
With donor restrictions	<u>-</u>	<u>1,823,287</u>	<u>1,823,287</u>	<u>1,077,672</u>
Total Net Assets	<u>753,767</u>	<u>1,823,287</u>	<u>2,577,054</u>	<u>1,987,039</u>
Total Liabilities and Net Assets	<u>1,384,380</u>	<u>1,823,287</u>	<u>3,207,667</u>	<u>2,639,179</u>

The accompanying notes to the financial statements
are an integral part of this statement.

Skylark Clinic, Inc.
d/b/a Skylark
Statements of Activities
For the Year Ending December 31, 2024
(with summarized comparative information for 2023)

	Without Donor Restrictions	With Donor Restrictions	Total	2023
Revenues and Other Support				
Banquet income	265,061	-	265,061	211,344
Banquet underwriting	107,751	-	107,751	98,188
Build for Life Campaign	-	740,175	740,175	975,943
Contributions	876,641	-	876,641	984,614
Contributions-non-cash	230,147	-	230,147	177,927
Christmas appeal	173,917	-	173,917	97,765
Grant revenue	-	-	-	68,600
Miscellaneous income	6,668	-	6,668	11,218
Interest income	2,777	30,485	33,262	13,364
Gain (loss) on sale of donated property	(2,595)	-	(2,595)	(395)
Released from Donor Restrictions	-	-	-	-
	<u>1,660,367</u>	<u>770,660</u>	<u>2,431,027</u>	<u>2,638,568</u>
Expenses				
Program expenses	1,397,115	-	1,397,115	1,490,891
Supporting expenses			-	
General and administrative	127,772	-	127,772	61,762
Fundraising	291,084	25,042	316,126	133,703
Total supporting expenses	<u>418,856</u>	<u>25,042</u>	<u>443,898</u>	<u>195,465</u>
Total Expenses	<u>1,815,971</u>	<u>25,042</u>	<u>1,841,013</u>	<u>1,686,356</u>
Change in net assets from operations	(155,604)	745,618	590,014	952,212
Net Assets, Beginning of Year, as previously stated	<u>897,552</u>	<u>154,236</u>	<u>1,051,788</u>	<u>1,051,788</u>
Net Assets, End of Year, as previously stated	<u>741,948</u>	<u>899,854</u>	<u>1,641,802</u>	<u>2,004,000</u>
Prior Period Adjustment	11,815	923,436	935,251	(16,961)
Net Assets, Beginning of Year, restated	<u>909,367</u>	<u>1,077,672</u>	<u>1,987,039</u>	<u>1,034,827</u>
Net Assets End of Year, restated	<u>753,763</u>	<u>1,823,290</u>	<u>2,577,053</u>	<u>1,987,039</u>

The accompanying notes to the financial statements
are an integral part of this statement.

Skylark Clinic, Inc.
d/b/a Skylark
Statements of Cash Flows
For the Years Ending December 31, 2024 and 2023

	<u>2024</u>	<u>2023</u>
Operational Activities		
Change in net assets	590,014	952,212
Adjustments to reconcile changes in net assets to net cash provided by operating activities		
Depreciation Expense	34,464	51,472
Amortization Expense	50,750	50,750
(Increase)/decrease in inventory	(21,813)	(47,822)
(Increase)/decrease in Pledge receivables	(50,340)	(950,053)
(Increase)/decrease in prepaid expenses	1,367	(21,153)
(Increase)/decrease in refundable deposits	-	-
Increase/(decrease) in accounts payable	32,143	15,970
Increase/(decrease) in accrued expenses	(21,058)	19,438
Net cash Provided (used) by operating activities	<u>615,527</u>	<u>70,814</u>
Investing Activities		
Purchase of fixed assets	(93,315)	(27,535)
Donated property held for sale	(21,987)	-
Net cash provided (used) by investing activities	<u>(115,302)</u>	<u>(27,535)</u>
Financing Activities		
Payment on Right to use asset - Lease obligation	(32,612)	(30,646)
Payments on EDIL loan	-	(145,031)
Net cash provided (used) by financing activities	<u>(32,612)</u>	<u>(175,677)</u>
Net Increase/(decrease) in Cash and Cash Equivalents	467,614	(132,398)
Cash and Cash Equivalents, Beginning of Year	<u>685,440</u>	<u>817,838</u>
Cash and Cash Equivalents, End of Year	<u><u>1,153,054</u></u>	<u><u>685,440</u></u>

The accompanying notes to the financial statements
are an integral part of this statement.

Skylark Clinic, Inc.
d/b/a Skylark
Statements of Functional Expenses
For the Year Ending December 31, 2024
(with summarized comparative information for 2023)

	Program Services	Supporting Services		Total Supporting Expenses	Total	2023
		General & Administration	Fundraising			
Abstinence education expense	21,610			-	21,610	25,932
Advertising expense	40,515			-	40,515	18,522
Bank and credit card charges	18,033	751		751	18,784	15,761
Banquet and fundraising expenses	-		147,870	147,870	147,870	133,703
Benevolence - Clients	172,355			-	172,355	133,229
Build for life Expense	-		25,042	25,042	25,042	36,334
Conferences and seminars	10,277			-	10,277	10,558
Dues and Subscriptions	5,062	211		211	5,273	3,600
Educational literature	7,491			-	7,491	6,625
Employee benefits	21,420	893		893	22,313	21,892
Food and entertainment	404			-	404	693
Fuel expense	10,450	435		435	10,885	12,839
Insurance expense	21,093	1,922		1,922	23,015	16,661
Interest expense	19,036			-	19,036	25,878
Legal and professional expense	3,644	14,576		14,576	18,220	15,231
Office expense	18,759	782		782	19,541	28,975
Post-abortion counseling	211			-	211	156
Postage expense	8,096	1,012	1,012	2,024	10,120	9,999
Penalties	608			-	608	-
Pregnancy tests expense	-			-	-	-
Public education expense	6,225			-	6,225	-
Rent expense	-			-	-	-
Repairs and maintenance	32,174	1,341		1,341	33,515	29,577
Salaries and wages	758,191	96,130	132,272	228,402	986,593	902,828
Software	10,573	441		441	11,014	-
Payroll taxes	58,699	7,752	9,930	17,682	76,380	71,186
Medical supplies	13,235			-	13,235	10,865
Taxes and licenses	2,491	101		101	2,592	5,110
Telephone expense	13,722	572		572	14,294	14,410
Training expense	8,031			-	8,031	2,219
Travel expense	3,097			-	3,097	1,878
Utilities expense	20,501	853		853	21,354	23,503
Volunteer expense	5,897			-	5,897	5,970
	<u>1,311,901</u>	<u>127,772</u>	<u>316,126</u>	<u>443,898</u>	<u>1,755,799</u>	<u>1,584,134</u>
Depreciation expense	34,464			-	34,464	51,472
Amortization expense	50,750			-	50,750	50,750
Total expenses	<u>1,397,115</u>	<u>127,772</u>	<u>316,126</u>	<u>443,898</u>	<u>1,841,013</u>	<u>1,686,356</u>

The accompanying notes to the financial statements
are an integral part of this statement.

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

Note 1 – Organization and Summary of Significant Accounting Policies

Organization

Skylark Clinic, Inc. (Skylark) operates as an extension of the local church as an outreach of Christian ministry. Skylark is committed to meeting women's spiritual, emotional and physical needs with pregnancy-related concerns without cost to the clients. Skylark was formed in Brunswick, Georgia, in 1992 and is dependent upon the generous support of individuals and organizations. Satellite centers were opened in Jesup, Georgia in October of 1999, in Kingsland, Georgia in 2003, and a mobile medical unit in 2017.

In October of 2017, the Board of Directors chose to adopt a new trade name for Skylark that would be more culturally acceptable and enable Skylark to reach more clients. The trade name is Skylark, A Sexual Health + Care Clinic.

Income Taxes

Skylark is exempt from paying income taxes on its exempt activities under Section 501(c)(3) of the Internal Revenue Code. Skylark files information returns in the U.S. federal jurisdiction and one state jurisdiction. Skylark uses a calendar year for tax reporting. Skylark is generally no longer subject to federal or state tax audits for years before 2011. Interest and penalties are expensed as incurred. No interest and penalties were charged to expense for the tax years ended December 31, 2024 and 2023.

Basis of Accounting

Skylark prepares its financial statements on the accrual basis of accounting following generally accepted accounting principles and reflects all significant receivables, payables and other liabilities.

Basis of Presentation

Financial statement presentation follows the recommendations of the Financial Accounting Standards Board and its Accounting Standards Codification (ASC) 958, *Not-For-Profit Entities*.

:

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

Net assets: Under ASC 958, Skylark must report information regarding its net assets and changes in net assets in two classes, which are based upon the existence or absence of restrictions on use that its donors place. These classes are as follows

Without donor restrictions: The portion of net assets whose use is not restricted by donors, even though their use may be limited in other respects, such as by board designation.

With donor restrictions: The portion of net assets used is subject to donor-imposed restrictions.

Use of estimates: Preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect specific reported amounts and disclosures. The organization's management believes that the estimates and assumptions are reasonable in the circumstances; however, the actual results could differ from those estimates.

Cash and cash equivalents: All unrestricted instruments with original maturities of three months or less are considered cash equivalents for financial statement purposes. Skylark had no cash equivalents as of December 31, 2024 and 2023.

Contributions: Skylark accounts for contributions following the Financial Accounting Standards Board ASC 958, *Not-For-Profit Entities* and ASC 310, *Receivables*. The contributions received are recorded as assets with or without donor restrictions, depending on the existence or nature of any donor restrictions. Contributions of donated noncash assets are recorded at their fair values in the period received.

All donor restricted support is reported as an increase in net assets with donor restrictions depending upon the nature of the restriction. When a restriction expires (when a stipulated time restriction ends or purpose restriction is accomplished), the net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

Promises to Give: Contributions are recognized when the donor makes a promise to give to the Organization that is, in substance, unconditional. Contributions that are restricted by the donor are reported as increases in net assets without donor restrictions if the restrictions

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

expire in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions.

When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions. The Organization uses the allowance method to determine uncollectible promises receivable. The allowance is based on prior years' experience and management's analysis of specific promises made.

The organization has discounted the pledge receivable using the net present value discount rate of 4.3%. This pledge receivable listed on the statement of Financial Position is net of the net present value discount of \$65,746.

Accounting for Leases: The organization adopted ASC 842 of the FASB standard update No. 2016-02, *Leases*. The organization capitalizes lease obligations as a right-to-use asset on the statement of position. A lease obligation is also presented on the statement of position as a short-term and long-term liability. Each year the organization will recognize interest expense associated with the lease obligation and amortization of the right to use asset over the lease term.

Functional allocation of expenses: The costs of providing various programs and supporting services have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the program and supporting services benefited.

Program services: Activities that result in services that fulfill the purpose or mission of the organization. Program services are the major purpose for and the major output of the organization.

Supporting services: Activities that are not identifiable with a specific program, fundraising activity, or program activity, but are indispensable to the organization.

General and administrative services: The general and administrative services include expenditures to secure proper administrative functioning, maintain the building, and manage the financial responsibilities of the organization.

Fundraising: The fundraising service includes expenditures that encourage and secure financial support for the organization.

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

Concentrations

Credit risk: The organization maintains its cash in bank deposit accounts which, on occasion, may exceed federally insured limits. Management continually monitors the soundness of these financial institutions and believes the loss exposure to be minimal.

Property and Equipment

Acquisitions of fixed assets over \$2,500 are capitalized. Purchased property and equipment are stated at cost. Donated property and equipment are recorded at the estimated fair market value on the date received. Major repairs and improvements are capitalized and depreciated. The cost and accumulated depreciation of property retired, sold or disposed of are removed from the related accounts with any gain or loss credited to or charged to income. Depreciation for furniture and equipment is calculated on the 200 percent declining method over the estimated useful life of the assets. Estimated useful lives are as follows:

<u>Type of Property</u>	<u>Estimated Useful Life</u>
Buildings and Improvements	39 years
Leasehold improvements	15 years
Furniture, fixtures, and Equipment	3-7 years

Depreciation expense recognized for the years ended December 31, 2024 and 2023 was \$34,464 and \$51,472 respectively.

Donated Facilities, Services and Materials

Skylark receives significant donated services from unpaid volunteers who provide services to clients and the clinic. Donated services are valued and reported at the estimated fair market value in the financial statements based on current rates for similar services.

Beginning with the fiscal year ended September 30, 2008, Skylark adopted a means of accounting for donated material that are subsequently given to clients, such as diapers,

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

children's clothing and furniture. A physical inventory of donated goods is maintained and valued based upon thrift store prices. Items received are recorded as in-kind donations (noncash donations), and items given to clients are recorded as benevolence-clients. All non-cash donations were recorded correctly when received in 2024.

Recent Accounting Pronouncements

The Financial Accounting Standards Board issued Update No. 2016-14 to ASC Topic 958, *Not-for-Profit Entities* in August of 2016. The main provisions of this update changed the classes of net assets from three (unrestricted, temporarily restricted, and permanently restricted) to two classes: net assets with donor restrictions and net assets without donor restrictions. The update also enhanced disclosures regarding governing board designations, liquidity of financial assets to meet cash needs for general expenditures within one year of the balance sheet date, and disclosing expenses by both their natural and functional classifications. The above-mentioned changes only highlight a portion of the changes in the amendment. It is recommended that the amendment is reviewed in its entirety. View Update No. 2016-14 by visiting the FASB website at fasb.org.

Accounting for Leases: The organization adopted FASB standard update No. 2016-02, *Leases*. The organization capitalizes lease obligations as a right-to-use asset on the statement of position. A lease obligation is also presented on the statement of position as a short-term and long-term liability. Each year the organization will recognize interest expense associated with the lease obligation and amortization of the right to use asset over the lease term.

Note 2 – Operating Leases

Skylark has no operating leases outside of the lease agreement for the Camden County and Wayne County real estate offices they reside in. These leases are capitalized as a right-to-use asset on the statement of financial position and have a lease obligation which is presented as a short-term and long-term liability. Below shows the current year impact to the financial statements.

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

	<u>2024</u>	<u>2023</u>
<u>Assets</u>		
Right to use - Lease obligation	659,749	659,749
Accumulated amortization of right to use asset	(152,250)	(101,500)
<u>Liabilities</u>		
Short-term - Lease obligation	48,865	32,612
Long-term - Lease obligation	519,090	567,955
<u>Statement of net position</u>		
Interest Expense	19,036	25,878
Amortization	50,750	50,750

Note 3 – Retirement Plan

Skylark participates in a SIMPLE IRA plan. Employees employed for 90 days and at least 28 hours a week can participate in the plan. Skylark matches employee contributions up to 3%. All employees participating are 100% vested in the plan. As of December 31, 2024 and 2023, Skylark paid \$22,313 and \$21,892 in employer matching expense, respectively.

Note 4 – Restatement

Correction of an error

Certain amounts in the consolidated financial statements of prior years have been corrected to conform to current year presentation. It was discovered that several beginning balances on the statement of financial position were incorrectly reported to conform with Generally Accepted Accounting Principles. The previous report incorrectly reported Pledge Receivables, Construction in progress, Intangible right to use lease assets, Amortization of right to use assets, short-term and long-term lease obligations and both unassigned and restricted fund balance. There were also changes to the Statement of Activities and Statement of Functional Expenses. Build for life campaign revenue and contribution revenue were corrected on the Statement of Activities. On the Statement of Functional expenses, the Build for life Expense, Interest Expense, Rent Expense, and Amortization Expense lines were corrected to reflect correct reporting in compliance with Generally Accepted Accounting Principles. Below is a breakout of the correction of errors made.

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

	2023	2023	
	2023	As corrected	Change
Assets			
Cash	340,828	341,013	185
Pledge Receivables	-	950,053	950,053
Construction in progress	-	27,535	27,535
Intangible right to use - Lease	-	659,749	659,749
Amortization of right to use	-	(101,500)	(101,500)
Liabilities			
Accounts payable	17,961	18,165	204
Lease payable due in one year	-	32,612	32,612
Lease payable due in more than one year	-	567,955	567,955
Net Assets			
Undesignated	647,552	657,983	10,431
With Donor Restrictions	154,236	1,077,672	923,436
Total Net Assets	1,051,788	1,947,802	896,014
Revenues and other support			
Build for life Campaign	110,043	975,943	865,900
Contributions	884,461	984,614	100,153
Functional Expenses			
Build for life Expense	49,369	36,334	(13,035)
Interest Expense	5,843	25,878	20,035
Rent Expense	49,200	-	(49,200)
Amortization Expense	-	50,750	50,750

Note 5 – Liquidity and Availability of Assets

The organization has \$2,284,013 of current financial assets as of December 31, 2024 consisting of cash of \$645,941, investments of \$507,113, prepaid expenses of \$19,786 and pledge receivables of \$1,000,393. Of this total financial asset, \$1,715,337 is subject to donor restrictions that require the funds to be used for specific projects not scheduled to occur within one year. Therefore, these assets are not available for general expenditures within the next year. Consequently, the total financial assets available within one year for general expenditures amount to \$568,676, excluding the donor-restricted funds.

Skylark Clinic, Inc.
d/b/a Skylark
Notes to Financial Statements
For the Year Ending December 31, 2024 and 2023

Also, Skylark Clinic, Inc. applied for and received a Thirty-year Economic Injury Disaster Loan of \$150,000. This loan was to be paid back twelve months from the date of the Note, which is June 19, 2020, at the rate of \$641 per month at an annual interest rate of 2.75%. Skylark began making payment sin August 2021. The loan was paid in full on June 12, 2023. The balance as of December 31, 2024 is \$0.

Note 6 – Capital Campaign

The organization intends to renovate their current Glynn County facility to better accommodate their mission. To fund the building project, the organization has raised \$1,900,411 in funds for this project, of which \$30,485 of interest has been earned on the capital campaign funds and is also restricted. Of the amount raised, the organization has spent \$169,326 in construction in progress and Capital Campaign related expenses. The board has also matched \$50,000 of contributions as of the end of the fiscal year.

The total capital project costs are projected to be \$3,322,917 for phase I and an additional \$1,709,301 for phase II for a total project cost of \$5,032,218. This amount includes \$1,000,000 of operating costs for the first five years.

Note 7 – Subsequent Events

Skylark's date for evaluating the existence of subsequent events that would affect the financial statements for the year ended December 31, 2024, was May 15, 2025, which was the date the financial statements were issued. No material subsequent events have come to our attention.